Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation.
Saved in:
| Title: | Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation. |
|---|---|
| Authors: | Cmarik EA; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana.; Purdue Institute for Drug Discovery, West Lafayette, Indiana., Wahi A; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana., Chandekar SS; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana., Otchere SK; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana., Sturgis JE; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana., Salhotra S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Basanthakumar AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boyd NX; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana., DiGiovanni G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Zhu H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Alexe G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Schaefer DA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Liu X; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana.; Purdue Institute for Drug Discovery, West Lafayette, Indiana.; Department of Biochemistry, Purdue University, West Lafayette, Indiana., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Mabe NW; Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana.; Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana.; Purdue Institute for Drug Discovery, West Lafayette, Indiana. |
| Source: | Molecular cancer research : MCR [Mol Cancer Res] 2026 Jul 02; Vol. 24 (7), pp. 555-575. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101150042 Publication Model: Print Cited Medium: Internet ISSN: 1557-3125 (Electronic) Linking ISSN: 15417786 NLM ISO Abbreviation: Mol Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
